Key Highlights
- Cardinal Health elevated its full-year adjusted EPS forecast to a range of $10.70–$10.80, improving from the prior $10.15–$10.35 outlook.
- Third-quarter adjusted EPS reached $3.17, surpassing the analyst consensus of $2.79.
- Total revenue increased 11% year-over-year to $60.9 billion, falling below the $62.1 billion Street projection.
- Net income declined to $399 million from $506 million, impacted by a $184 million goodwill impairment charge.
- CAH shares advanced 1.6% during premarket hours on Thursday.
Cardinal Health delivered its second upward revision to annual profit expectations this fiscal year, catching the market’s favorable attention. Shares climbed 1.6% in Thursday’s premarket session, reaching $205.99.
The healthcare giant now anticipates adjusted earnings between $10.70 and $10.80 per share for fiscal year 2026. This represents a meaningful increase from the $10.15 to $10.35 range provided in February. The Street consensus had settled around $10.31 per share.
The improved outlook provided significant support for the stock. However, the quarterly performance itself presented a more nuanced picture.
On the earnings front, adjusted EPS of $3.17 handily exceeded the $2.79 analyst projection. This represented a substantial positive surprise.
Revenue performance, however, painted a less favorable picture. While total sales advanced 11% compared to the prior-year period to reach $60.9 billion, this figure came up short of the $62.1 billion consensus expectation.
The pharmaceutical and specialty solutions division accounted for the bulk of revenue expansion, generating $56.1 billion—an 11% increase from the comparable quarter last year.
Meanwhile, the global medical products and distribution segment struggled. Sales in this division remained essentially unchanged year-over-year, pressured by reduced distribution volumes.
Bottom Line Under Pressure
Net earnings fell to $399 million from $506 million reported in the same quarter a year earlier. The primary driver was a pretax goodwill impairment charge totaling $184 million.
This charge stemmed from Cardinal’s oncology practice alliance and Integrated Oncology Network, an asset the company brought into its portfolio in late 2024.
While goodwill impairment charges don’t represent actual cash outflows, they indicate that an acquired business unit is underperforming relative to initial expectations at the time of purchase. Such developments warrant careful consideration.
Evercore ISI analyst Elizabeth Anderson characterized the quarterly performance as “solid,” highlighting that the pharmaceutical revenue shortfall stemmed primarily from wholesale acquisition cost dynamics—a passthrough accounting matter rather than an underlying operational weakness.
Specialty Pharmaceuticals Drive Forward Guidance
Cardinal Health, alongside industry counterparts Cencora and McKesson, continues benefiting from robust demand for higher-margin specialty pharmaceutical products. Medications targeting oncology and autoimmune conditions represent a growing proportion of the distribution portfolio.
Biosimilar introductions for previously patent-protected blockbuster medications are also contributing to volume expansion. These product categories enable distributors to capture enhanced margins compared to conventional generic pharmaceuticals.
Cardinal has been strategically expanding its specialty healthcare presence through targeted acquisitions of physician practices and specialty distribution networks. The Integrated Oncology Network transaction exemplified this strategic approach.
This strategy hasn’t proceeded without challenges—the current quarter’s impairment charge underscores this reality. Nevertheless, management appears committed to maintaining this strategic trajectory.
The second consecutive quarterly upgrade to full-year guidance demonstrates management’s confidence in performance during the remainder of the fiscal year.
Cardinal Health’s fiscal third quarter concluded on March 31. At the time of publication, shares traded 1.6% higher at $205.99 in premarket activity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
